The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
Abstract
Pegylated liposomal doxorubicin (Doxil, Caelyx) is a formulation of doxorubicin in poly(ethylene glycol)-coated (stealth) liposomes with a prolonged circulation time and unique toxicity profile. We review the preclinical and clinical pharmacology as well as recent clinical data obtained in specific cancer types. Doxil liposomes retain the drug payload during circulation and accumulate preferentially in tissues with increased microvascular permeability, as often is the case of tumors. Doxil toxicity profile is drastically different from that of doxorubicin, and is characterized by dominant and dose-limiting mucocutaneous toxicities, mild myelosuppression, minimal alopecia, and no apparent cardiac toxicity. Although the single maximum tolerated dose (MTD) of Doxil is actually lower than that of conventionally administered doxorubicin, the cumulative MTD dose of Doxil may be substantially greater than that of free doxorubicin. Doxil is probably one of the most active agents in AIDS-related Kaposi's sarcoma and has a definite role in management of recurrent ovarian cancer. The potential of Doxil in the treatment of other cancer types and the opportunities it offers in combination with other drugs and therapeutic modalities are under active investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Doxorubicin encapsulated in a liposome (Doxil), administrated intravenously, has been used to treat breast cancer, ovarian cancer, Kaposi's sarcoma, and other solid tumors.”
From Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
Research works printed but not linked: 76
- Lasic D. D., 1998, Medical Applications of Liposomes
- Janoff A. S., 1999, Liposomes: Rational Design
- Markman M, 1997, Drugs, 54, 1
- Alberts D. S, 1997, Oncology, 11, 1
- Lasic D., 1995, Stealth Liposomes
- 10.1007/978-3-662-22115-0 · DOI
- 10.1073/pnas.88.24.11460 · DOI · Paper page
- 10.1016/0005-2736(90)90091-2 · DOI · Paper page
- 10.1016/0014-5793(92)80947-F · DOI · Paper page
- Gabizon A., 1990, Cancer Res., 50, 6371
- Yuan F., 1995, Cancer Res., 55, 3752
- 10.1023/A:1018907715905 · DOI · Paper page
- 10.1177/096032719601500906 · doi:10.1177/096032719601500906
- 10.1016/S0169-409X(96)00476-0 · DOI · Paper page
- 10.1038/bjc.1997.84 · DOI
- 10.2165/00003495-199700544-00005 · DOI · Paper page
- 10.3109/10611869608996830 · DOI
- Hong R-L., 1999, Clin. Cancer Res., 5, 3645
- 10.3109/08982109909035551 · DOI
- 10.3109/08982109309150734 · DOI
- Working P. K., 1999, J. Pharmacol Exp. Ther., 289, 1128
- Gabizon A., 1994, Cancer Res., 54, 987
- Martin F. J, 1997, Oncology, 11, 11
- 10.1016/S0009-9236(97)90162-4 · doi:10.1016/s0009-9236(97)90162-4
- 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z · DOI · Paper page
- 10.1002/j.1552-4604.1996.tb04152.x · DOI · Paper page
- Stewart S., 1997, Oncology, 11, 33
- 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1 · DOI · Paper page
- Uziely B., 1995, J. Clin. Oncol., 13, 1777, 10.1200/JCO.1995.13.7.1777 · DOI · Paper page
- Ranson M. R., 1997, J. Clin. Oncol., 15, 3185, 10.1200/JCO.1997.15.10.3185 · DOI · Paper page
- Muggia F. M., 1997, J. Clin. Oncol., 15, 987, 10.1200/JCO.1997.15.3.987 · DOI · Paper page
- Hamilton A., 1998, Breast Cancer Res. Treat., 50, 324
- 10.1007/978-3-662-22115-0_11 · DOI
- 10.1097/00001813-199801000-00005 · DOI
- 10.1006/bbrc.1994.2658 · DOI
- 10.1097/00001813-200002000-00009 · DOI
- Huang S. K., 1994, Cancer Res., 54, 2186
- 10.1007/BF00685327 · DOI
- Gill P. S., 1995, J. Clin. Oncol., 13, 996, 10.1200/JCO.1995.13.4.996 · DOI · Paper page
- Vail D. M., 1998, Clin. Cancer Res., 4, 1567
- 10.1023/A:1008216430806 · DOI · Paper page
- 10.1023/A:1008365716693 · DOI · Paper page
- 10.1093/jnci/87.20.1556 · doi:10.1093/jnci/87.20.1556
- 10.1023/A:1008364529537 · doi:10.1023/a:1008364529537
- 10.1016/S0936-6555(05)80089-5 · doi:10.1016/s0936-6555(05)80089-5
- Harrison M., 1995, J. Clin. Oncol., 13, 914, 10.1200/JCO.1995.13.4.914 · doi:10.1200/jco.1995.13.4.914
- Northfelt D. W., 1998, J. Clin. Oncol., 16, 2445, 10.1200/JCO.1998.16.7.2445 · DOI · Paper page
- Stewart S., 1998, J. Clin. Oncol., 16, 683, 10.1200/JCO.1998.16.2.683 · DOI · Paper page
- Gill P. S., 1996, J. Clin. Oncol., 14, 2353, 10.1200/JCO.1996.14.8.2353 · DOI · Paper page
- Northfelt D. W., 1997, J. Clin. Oncol., 15, 653, 10.1200/JCO.1997.15.2.653 · DOI · Paper page
- Gordon A. N., 2000, Proc. Am. Soc. Clin. Oncol., 19, 1504
- Klein P., 2000, Proc. Am. Soc. Oncol., 19, 410a
- 10.1016/S0190-9622(00)90007-0 · doi:10.1016/s0190-9622(00)90007-0
- 10.1023/A:1008386822906 · doi:10.1023/a:1008386822906
- Ellerhorst J. A., 1999, Oncol. Rep., 6, 1097
- 10.1023/A:1008439013169 · DOI
- Judson I., 1999, Proc. Am. Soc. Clin. Oncol., 18, 541a
- 10.1023/A:1008319618638 · doi:10.1023/a:1008319618638
- 10.1002/(SICI)1096-8652(199801)57:1<85::AID-AJH16>3.0.CO;2-8 · doi:10.1002/(sici)1096-8652(199801)57:1<85::aid-ajh16>3.0.co;2-8
- 10.1016/S0959-8049(99)81571-8 · doi:10.1016/s0959-8049(99)81571-8
- Langley R. E., 1998, Proc. Am. Soc. Clin. Oncol., 17, 246a
- Wasserheit C., 1999, Proc. Am. Soc. Clin. Oncol., 18, 167a
- 10.1023/A:1008323200102 · DOI
- Lokich J., 1983, J. Clin. Oncol., 1, 24, 10.1200/JCO.1983.1.1.24 · DOI
- Samuels B. L., 1987, Cancer Treat. Rep., 71, 971
- Krishna R., 1999, Anticancer Res., 19, 2885
- Cabanes A., 1999, Clin. Cancer Res., 5, 687
- Colbern G. T., 1998, Breast Cancer Res. Treat., 50, 320
- Koukourakis M. I., 1999, J. Clin. Oncol., 17, 3512, 10.1200/JCO.1999.17.11.3512 · DOI · Paper page
- Lopez de Menezes D. E., 1998, Cancer Res., 58, 3320
- 10.1016/S0168-3659(97)00236-8 · DOI · Paper page
- 10.1073/pnas.92.5.1327 · DOI · Paper page
- 10.1038/bjc.1996.625 · DOI · Paper page
- 10.3109/08982109009036010 · DOI
- 10.1016/B978-044482917-7/50035-1 · doi:10.1016/b978-044482917-7/50035-1
- Martin F. J. Medical Applications of Liposomes, D. D. Lasic, D. Papahadjopoulos. Elsevier, New York 1998; 654
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Exploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846
Metadata
- Authors
- Gabizon, A. A.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2001-01
- Volume
- 19
- Issue
- 4
- Pages
- 424-436
- ISSN
- 0735-7907
- 1532-4192
- Cited by
- 458
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.